330 related articles for article (PubMed ID: 27644763)
1. Tumor-Associated Macrophages and Myeloid-Derived Suppressor Cells as Immunosuppressive Mechanism in Ovarian Cancer Patients: Progress and Challenges.
Okła K; Wertel I; Polak G; Surówka J; Wawruszak A; Kotarski J
Int Rev Immunol; 2016 Sep; 35(5):372-385. PubMed ID: 27644763
[TBL] [Abstract][Full Text] [Related]
2. Myeloid suppressor cells in cancer and autoimmunity.
Sica A; Massarotti M
J Autoimmun; 2017 Dec; 85():117-125. PubMed ID: 28728794
[TBL] [Abstract][Full Text] [Related]
3. Myeloid-derived suppressor cells and their role in pancreatic cancer.
Pergamo M; Miller G
Cancer Gene Ther; 2017 Mar; 24(3):100-105. PubMed ID: 27910857
[TBL] [Abstract][Full Text] [Related]
4. Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets.
Szebeni GJ; Vizler C; Nagy LI; Kitajka K; Puskas LG
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27886105
[TBL] [Abstract][Full Text] [Related]
5. Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers.
Fujimura T; Aiba S
Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32707850
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive Role of Myeloid-Derived Suppressor Cells and Therapeutic Targeting in Lung Cancer.
Ma J; Xu H; Wang S
J Immunol Res; 2018; 2018():6319649. PubMed ID: 29765990
[TBL] [Abstract][Full Text] [Related]
7. Metabolomic profiling of tumor-infiltrating macrophages during tumor growth.
Umemura N; Sugimoto M; Kitoh Y; Saio M; Sakagami H
Cancer Immunol Immunother; 2020 Nov; 69(11):2357-2369. PubMed ID: 32518979
[TBL] [Abstract][Full Text] [Related]
8. Myeloid-Derived Suppressor Cells (MDSCs) in Ovarian Cancer-Looking Back and Forward.
Okła K
Cells; 2023 Jul; 12(14):. PubMed ID: 37508575
[TBL] [Abstract][Full Text] [Related]
9. Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer.
Okła K; Czerwonka A; Wawruszak A; Bobiński M; Bilska M; Tarkowski R; Bednarek W; Wertel I; Kotarski J
Front Immunol; 2019; 10():691. PubMed ID: 31001284
[TBL] [Abstract][Full Text] [Related]
10. Metformin induces CD11b+-cell-mediated growth inhibition of an osteosarcoma: implications for metabolic reprogramming of myeloid cells and anti-tumor effects.
Uehara T; Eikawa S; Nishida M; Kunisada Y; Yoshida A; Fujiwara T; Kunisada T; Ozaki T; Udono H
Int Immunol; 2019 Mar; 31(4):187-198. PubMed ID: 30508092
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Dysthe M; Parihar R
Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated myeloid cells as guiding forces of cancer cell stemness.
Sica A; Porta C; Amadori A; Pastò A
Cancer Immunol Immunother; 2017 Aug; 66(8):1025-1036. PubMed ID: 28401258
[TBL] [Abstract][Full Text] [Related]
13. The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Kumar V; Patel S; Tcyganov E; Gabrilovich DI
Trends Immunol; 2016 Mar; 37(3):208-220. PubMed ID: 26858199
[TBL] [Abstract][Full Text] [Related]
14. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.
Nakamura K; Smyth MJ
Cell Mol Immunol; 2020 Jan; 17(1):1-12. PubMed ID: 31611651
[TBL] [Abstract][Full Text] [Related]
15. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives.
Ibáñez-Vea M; Zuazo M; Gato M; Arasanz H; Fernández-Hinojal G; Escors D; Kochan G
Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):113-123. PubMed ID: 29032490
[TBL] [Abstract][Full Text] [Related]
16. The immunobiology of myeloid-derived suppressor cells in cancer.
Motallebnezhad M; Jadidi-Niaragh F; Qamsari ES; Bagheri S; Gharibi T; Yousefi M
Tumour Biol; 2016 Feb; 37(2):1387-406. PubMed ID: 26611648
[TBL] [Abstract][Full Text] [Related]
17. Myeloid-derived suppressor cells: Important contributors to tumor progression and metastasis.
Safarzadeh E; Orangi M; Mohammadi H; Babaie F; Baradaran B
J Cell Physiol; 2018 Apr; 233(4):3024-3036. PubMed ID: 28661031
[TBL] [Abstract][Full Text] [Related]
18. Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment.
Tian X; Shen H; Li Z; Wang T; Wang S
J Hematol Oncol; 2019 Aug; 12(1):84. PubMed ID: 31438991
[TBL] [Abstract][Full Text] [Related]
19. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages.
Liu Z; Xie Y; Xiong Y; Liu S; Qiu C; Zhu Z; Mao H; Yu M; Wang X
Cancer Lett; 2020 Jan; 469():173-185. PubMed ID: 31629935
[TBL] [Abstract][Full Text] [Related]
20. A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment.
Hofer F; Di Sario G; Musiu C; Sartoris S; De Sanctis F; Ugel S
Cells; 2021 Oct; 10(10):. PubMed ID: 34685679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
